
Amgen (AMGN) has been in focus after a packed early November. Fresh third quarter figures, new real world Repatha data and progress in obesity and autoimmune programs all arrived within days.
Investors have reacted to this flurry of updates with a clear shift in mood. Amgen's share price has climbed 11.1% over the past 90 days and logged a 40.5% year to date share price return. The 5 year total shareholder return of 157.2% points to momentum that has been building over a longer stretch as earnings, guidance, product data and even regulatory scrutiny have all landed in quick succession.
Scan how Amgen’s surge, fresh trial data and pipeline momentum compare with other large healthcare players by zeroing in on our curated list of solid balance sheet and fundamentals (25 results)
After a near US$460 share price and a packed run of product news, Amgen now poses a clearer question for you as an investor: Does the current valuation still leave enough upside to justify the risk?
Amgen last closed at $460.42, while the most followed narrative on Simply Wall St pegs fair value at $359.98. According to AnimalDoctorKwon, a Simply Wall St Community investor who wrote the narrative, that gap reflects a fundamental mismatch between hype and the current business mix.
The "Amgen 2027 Bull Case" relies on a classic top-line fallacy: assuming that macro obesity market growth and FDA's CNPV (Commissioner’s National Priority Voucher) tailwinds will automatically trigger a re-rating.
Here is the cold, data-driven reality:
See why 8 investors see Amgen as 28% overvalued.
Result: Fair Value of $359.98 (OVERVALUED)
Still, faster-than-expected MariTide execution or slower erosion in Prolia and Enbrel could pressure this overvaluation thesis and reframe Amgen’s risk-reward profile.
Find out about the key risks to this Amgen narrative.
On simple earnings multiples, Amgen sends a very different signal. The shares trade on a P/E of 26.5x, which is cheaper than the peer average of 52.3x and below a fair ratio of 34.6x that the market could move toward over time. Compared with the US Biotechs industry on 15.4x, that still implies you are paying a premium for quality. The key question is whether that premium feels like a sensible trade off or a stretch at $460.42.
See what the numbers say about this price — find out in our valuation breakdown.
Sentiment on Amgen is clearly split, with clear risks on one side and meaningful potential rewards on the other. Move quickly, review the data for yourself and weigh up the 4 key rewards and 1 important warning sign
If Amgen has sharpened your thinking, do not stop there. Use fresh screeners to spot other opportunities that fit your style before the crowd does.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com